Penserra Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $543K | Sell |
591
-196
| -25% | -$199K | 0.01% | 547 |
|
|
2025
Q4 | $845K | Buy |
787
+217
| +38% | +$207K | 0.01% | 471 |
|
|
2025
Q3 | $434K | Buy |
570
+24
| +4% | +$17.9K | 0.01% | 602 |
|
|
2025
Q2 | $425K | Sell |
546
-267
| -33% | -$207K | 0.01% | 544 |
|
|
2025
Q1 | $670K | Sell |
813
-2,100
| -72% | -$1.75M | 0.01% | 546 |
|
|
2024
Q4 | $2.25M | Buy |
2,913
+2,043
| +235% | +$1.69M | 0.04% | 292 |
|
|
2024
Q3 | $770K | Buy |
870
+271
| +45% | +$244K | 0.02% | 466 |
|
|
2024
Q2 | $543K | Buy |
599
+521
| +668% | +$417K | 0.01% | 562 |
|
|
2024
Q1 | $60K | Sell |
78
-3,624
| -98% | -$2.58M | ﹤0.01% | 865 |
|
|
2023
Q4 | $2.16M | Sell |
3,702
-2,354
| -39% | -$1.37M | 0.04% | 272 |
|
|
2023
Q3 | $3.25M | Buy |
6,056
+940
| +18% | +$484K | 0.07% | 200 |
|
|
2023
Q2 | $2.4M | Buy |
5,116
+5,064
| +9,738% | +$2.12M | 0.05% | 280 |
|
|
2023
Q1 | $17K | Hold |
52
| – | – | ﹤0.01% | 900 |
|
|
2022
Q4 | $19K | Buy |
+52
| New | +$18.4K | ﹤0.01% | 945 |
|
|
2022
Q3 | – | Sell |
-12,065
| Closed | -$3.91M | – | 1101 |
|
|
2022
Q2 | $3.91M | Buy |
12,065
+11,945
| +9,954% | +$3.59M | 0.11% | 199 |
|
|
2022
Q1 | $34K | Sell |
120
-36
| -23% | -$9.27K | ﹤0.01% | 1110 |
|
|
2021
Q4 | $43K | Hold |
156
| – | – | ﹤0.01% | 1060 |
|
|
2021
Q3 | $36K | Buy |
156
+11
| +8% | +$2.71K | ﹤0.01% | 1145 |
|
|
2021
Q2 | $33K | Buy |
+145
| New | +$29.1K | ﹤0.01% | 1082 |
|
|
2020
Q4 | – | Sell |
-540
| Closed | -$79K | – | 1083 |
|
|
2020
Q3 | $79K | Sell |
540
-32
| -6% | -$4.95K | ﹤0.01% | 550 |
|
|
2020
Q2 | $93K | Sell |
572
-103
| -15% | -$15.8K | ﹤0.01% | 572 |
|
|
2020
Q1 | $103K | Sell |
675
-137
| -17% | -$18.8K | 0.01% | 563 |
|
|
2019
Q4 | $114K | Buy |
812
+119
| +17% | +$13.8K | 0.01% | 549 |
|
|
2019
Q3 | $77K | Buy |
693
+273
| +65% | +$30.4K | 0.01% | 593 |
|
|
2019
Q2 | $46K | Sell |
420
-578
| -58% | -$68.1K | ﹤0.01% | 617 |
|
|
2019
Q1 | $129K | Sell |
998
-10,241
| -91% | -$1.25M | 0.01% | 411 |
|
|
2018
Q4 | $1.3M | Sell |
11,239
-7,434
| -40% | -$830K | 0.13% | 176 |
|
|
2018
Q3 | $2M | Buy |
18,673
+14,723
| +373% | +$1.47M | 0.12% | 118 |
|
|
2018
Q2 | $337K | Buy |
3,950
+606
| +18% | +$49.8K | 0.02% | 271 |
|
|
2018
Q1 | $258K | Buy |
3,344
+264
| +9% | +$21.3K | 0.02% | 236 |
|
|
2017
Q4 | $260K | Buy |
3,080
+484
| +19% | +$41.2K | 0.03% | 204 |
|
|
2017
Q3 | $224K | Buy |
2,596
+308
| +13% | +$25.3K | 0.05% | 185 |
|
|
2017
Q2 | $188K | Buy |
2,288
+264
| +13% | +$21.5K | 0.07% | 215 |
|
|
2017
Q1 | $170K | Buy |
2,024
+176
| +10% | +$14.1K | 0.02% | 238 |
|
|
2016
Q4 | $135K | Buy |
1,848
+264
| +17% | +$19.7K | 0.02% | 292 |
|
|
2016
Q3 | $127K | Buy |
1,584
+792
| +100% | +$63.4K | 0.02% | 231 |
|
|
2016
Q2 | $62K | Buy |
792
+264
| +50% | +$19.9K | 0.01% | 275 |
|
|
2016
Q1 | $38 | Buy |
528
+176
| +50% | +$13.3K | ﹤0.01% | 329 |
|
|
2015
Q4 | $30K | Buy |
+352
| New | +$29.2K | ﹤0.01% | 331 |
|
Other funds holding LLY
VCM
VPM
Penserra Capital Management's LLY Position: Q1 2026 in Review
Penserra Capital Management reduced its Eli Lilly (LLY) stake by 25% in Q1 2026, selling an estimated $199K and leaving 591 shares worth $543K. The position accounts for 0.01% of the portfolio, ranked #547.
Penserra Capital Management first reported a position in LLY in Q4 2015 and has held it in 39 quarters since. The position peaked at $3.91M in Q2 2022. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Penserra Capital Management held 591 shares of Eli Lilly worth $543K as of Q1 2026.
- Penserra Capital Management sold 196 Eli Lilly shares in Q1 2026, an estimated $199K.
- Eli Lilly made up 0.01% of Penserra Capital Management's portfolio in Q1 2026, its #547 holding.
- Penserra Capital Management first reported a position in Eli Lilly in Q4 2015 and has held it in 39 quarters since.
- Penserra Capital Management's Eli Lilly position peaked at $3.91M in Q2 2022.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.